Reig Jofre reaches a new milestone: 5 million vials of injectable Remifentanil marketed in Japan

  • Commemoration of this important milestone, which was reached thanks to the collaboration between Reig Jofre, Kern Pharma, Maruishi Pharma, Daiichi Sankyo and CBC
  • Reig Jofre is one of the world’s largest producers of Remifentanil, the latest generation injectable anesthetic for hospital use

Reig Jofre, a pharmaceutical company quoted on the Spanish continuous market, marked the closure of 2019 with an important milestone; the manufacture and marketing in Japan of the 5 millionth unit of Remifentanil vials, a new generation injectable anesthetic for hospital use. The product was developed internally by the company and is produced in its lyophilized injectables plant in Barcelona.

The celebration of this milestone took place in the Japanese city of Osaka, with the presence of representatives from the pharmaceutical companies that made this achievement possible: Reig Jofre, which contributed its expertise in the development and manufacture of sterile lyophilized injectables; Kern Pharma, with its capacity to synthesize the active substance in its Terrassa plant (Barcelona, Spain); Maruishi Pharmaceutical (Osaka), project leader and expert in hospital specialties and disinfectants/antiseptics and which, in conjunction with Daiichi Sankyo, is responsible for the commercialization of Remifentanil throughout the Japanese hospital network; and CBC, a trader specialized in the generation of business opportunities in Japan.

Download the full document (PDF)